PMC:7344504 / 112-432 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"17","span":{"begin":100,"end":108},"obj":"Species"},{"id":"21","span":{"begin":295,"end":303},"obj":"Chemical"},{"id":"25","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"26","span":{"begin":20,"end":43},"obj":"Disease"},{"id":"27","span":{"begin":121,"end":144},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"Tax:9606"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"MESH:D014230"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:C000657245"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"MESH:D055732"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:D008171"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agent"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T4","span":{"begin":30,"end":43},"obj":"Disease"},{"id":"T5","span":{"begin":45,"end":49},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"}],"text":"COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agent"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":54,"end":55},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":212,"end":213},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agent"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":231,"end":241},"obj":"Chemical"},{"id":"T3","span":{"begin":295,"end":303},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_38597"}],"text":"COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agent"}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":177},"obj":"Sentence"},{"id":"T5","span":{"begin":178,"end":250},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agent"}